Efficacy of calcium channel blocker in the secondary prevention of myocardial infarction - Retrospective analysis of the 10-year prognosis of coronary thrombolysis-treated patients

Circulation Journal

Volumn 68, Issue 9, 2004, Pages 853-859

  Tani, Shigemasa ^a   Watanabe, Ikuyoshi ^a   Nagao, Ken ^b   Kikushima, Kimio ^a   Watanabe, Kazuhiro ^a   Anazawa, Takeo ^a   Kawamata, Hirofumi ^a   Tachibana, Eizo ^a   Furuya, Shingo ^a   Sasanuma, Toshifumi ^a   Kushiro, Toshio ^a   Kanmatsuse, Katsuo ^a  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium channel blocker; Long term prognosis; Myocardial infarction (MI); Nifedipine retard; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRATE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEADACHE; HEART DEATH; HEART INFARCTION; HEART PALPITATION; HOT FLUSH; HUMAN; INCIDENCE; MALE; PROGNOSIS; RETROSPECTIVE STUDY; RISK; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; SURVIVAL;

AGED; CALCIUM CHANNEL BLOCKERS; CORONARY THROMBOSIS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NIFEDIPINE; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 4544305736     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.853     Document Type: Article

References (37)

1. The Israeli Sprint Study Group. Secondary Prevention Reinfarction Isreli Nifedipine Trial (SPRINT): A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354-364.
2. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction: The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993; 153: 345-353.
3. Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction: Secondary Prevention Group. Circulation 1997; 95: 2368-2373.
4. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. BMJ 1989; 299: 1187-1192.
5. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction: Evidence from clinical trials. N Engl J Med 1996; 335: 1660-1667.
6. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
7. Psaty BM, Furberg CD. Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonists. J Hypertens 1997; 15: 1197-1200.
8. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, et al. Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. Circulation 2000; 101: 1102-1108.
9. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: Differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999; 33: 1442-1452.
10. Akiyama H, Ishikawa K, Kanamasa K, Ogawa I, Koka H, Kamata N, et al. Increased coronary vasomotor tone in acute myocardial infarction patients with spontaneous coronary recanalization. Jpn Circ J 1997; 61: 503-509.
11. Ikegawa T, Chino M, Usuba F, Nishikawa K, Nakamura Y. Coronary angiography after myocardial infarction. A comparison between a Japanese community hospital and Western countries. Jpn Heart J 1986; 27: 279-285.
12. Hughes LO, Raval U, Raftery EB. First myocardial infarctions in Asian and white men. BMJ 1989; 298: 1345-1350.
13. Saito M, Fukami K, Hiramori K, Haze K, Sumiyoshi T, Kasagi H, et al. Long-term prognosis of patients with acute myocardial infarction: Is mortality and morbidity as low as the incidence of ischemic heart disease in Japan. Am Heart J 1987; 113: 891-897.
14. Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35: 742-749.
15. Hagiwara T, Mikami T, Tabuchi Y, Kumahara Y. Pharmacokinetic of BAY a 1040 (nifedipine) 20 mg tablet for 15 days administration in healthy male volunteers. Jpn Pharmacol Ther 1985; 13: 4481 (in Japanese).
16. The TIMI study group. The Thrombolysis in Myocardial Infarction (TlMI) trial. N Eng l J Med 1985; 312: 932-936.
17. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, editor. Heart disease: A text book of cardiovascular medicine. Philadelphia: WB Saunders; 1992; 756-789.
18. Ishikawa K, Miyataka M, Kanamasa K, Hayashi T, Takenaka T, Inoki T, et al. Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol: Secondary Prevention Group. Jpn Circ J 2000; 64: 358-364.
19. Yasue H, Nagao M, Omote S, Takizawa A, Miwa K. Tanaka S. Coronary arterial spasm and Prinzmetal's variant form of angina induced by hyperventilation and Tris-buffer infusion. Circulation 1978; 58: 56-62.
20. Shimokawa H, Nagasawa K, Irie T, Egashira S, Egashira K, Sagara T, et al. Clinical characteristics and long-term prognosis of patients with variant angina: A comparative study between western and Japanese populations. Int J Cardiol 1988; 18: 331-349.
21. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76-79.
22. Deanfield J, Wright C, Krikler S, Ribeiro P, Fox K. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. N Engl J Med 1984; 310: 951-954.
23. Nakashima Y, Kawashima T, Nandate H, Yashiro A, Kuroiwa A. Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. Am Heart J 1990; 119: 1267-1273.
24. Cody RJ. The hemodynamics of calcium-channel antagonists in hypertension: Vascular and myocardial responses. Circulation 1987; 75: 1175-1179.
25. Cleophas TJ, van Marum R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol 2001; 87: 487-490.
26. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240-245.
27. Schulman DS, Flores AR, Tugoen J, Dianzumba S, Reichek N. Anti-hypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. Am J Cardiol 1996; 78: 56-60.
28. Hirata A, Igarashi M, Yamaguchi H, Suwabe A, Daimon M, Kato T, et al. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br J Pharmacol 2000; 131: 1521-1530.
29. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335: 1109-1113.
30. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-1953.
31. Kleinbloesem CH, Van Brummelen P, Van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: Kinetics and dynamics in healty subjects. Clin Pharmacol Ther 1984; 6: 742-749.
32. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191.
33. Japanese Beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969-973.
34. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-1954.
35. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase. oral aspirin, both, or neither (The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group). BMJ 1998; 316: 1337-1343.
36. Ishikawa K, Miyataka M, Kimura A, Takeda N, Hirano Y, Hayashi T, et al. Secondary Prevention Group: Beta-blockers prevent cardiac events in Japanese patients with myocardial infarction. Circ J 2004; 68: 59-67.
37. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al J-LIT Study Group. Japan Lipid Intervention Trial: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087-1095.